Article
Cell Biology
Roberto Gedaly, Gabriel Orozco, Alexandre P. Ancheta, Mackenzie Donoho, Siddharth N. Desai, Fanny Chapelin, Aman Khurana, Lillie J. Lewis, Cuiping Zhang, Francesc Marti
Summary: This study aimed to compare the effects of AZD8055 and RAPA on the manufacturing of clinically competent Treg cells. The results showed that AZD8055 had a stronger inhibition on the mTORC2 signaling pathway and IL2-receptor downstream events compared to RAPA, but it also disrupted the long-term expansion and suppressive function of Tregs, and affected cellular metabolism and stress response pathways.
Article
Gastroenterology & Hepatology
Clement Barjon, Geraldine Dahlqvist, Khaldoun Ghazal, Faouzi Saliba, Francois Durand, Christophe Duvoux, Lynda Aoudjehane, Filomena Conti
Summary: This study monitored Tregs levels and functionality in liver transplant patients under different immunosuppressive drugs, finding that everolimus may have a more positive impact on Tregs compared to tacrolimus. This provides a new approach for reducing the use of immunosuppressive drugs.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2021)
Review
Immunology
Caroline Dudreuilh, Sumoyee Basu, Cristiano Scotta, Anthony Dorling, Giovanna Lombardi
Summary: Regulatory T cells like Tregs play a crucial role in maintaining immune balance and preventing autoimmune diseases. Specifically, Tfr cells regulate interactions between B cells and Tfh cells, and their potential applications in transplantation and immunosuppression warrant further exploration.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Sebastian Wolf, Verena S. Hoffmann, Florian Sommer, Matthias Schrempf, Mingming Li, Martin Ryll, Ulrich Wirth, Matthias Ilmer, Jens Werner, Joachim Andrassy
Summary: Based on network meta-analysis, ERL combined with CNI showed the strongest anti-CMV effect compared to regular CNI treatment (RR 0.27, CI 0.22-0.32, p <0.0001).
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Chengcheng Gong, Qin Xiao, Yi Li, Yajia Gu, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Yannan Zhao, Yizhao Xie, Xichun Hu, Biyun Wang
Summary: The study revealed that ERP occurred in more than half of patients with metastatic breast cancer treated with everolimus, and was associated with improved treatment outcomes.
Article
Immunology
Joanna Balcerek, Brian R. Shy, Amy L. Putnam, Lisa M. Masiello, Angela Lares, Florinna Dekovic, Luis Acevedo, Michael R. Lee, Vinh Nguyen, Weihong Liu, Sreenivasan Paruthiyil, Jingying Xu, Ashley S. Leinbach, Jeffrey A. Bluestone, Qizhi Tang, Jonathan H. Esensten
Summary: The manufacturing outcomes of PolyTreg products were consistent across different clinical trials and production dates, with cell fold expansion primarily correlated to the initial cell number. Parameters such as manufacturing date, patient sex, and age did not significantly affect Treg cell expansion during product manufacturing.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Lissa Pipeleers, Daniel Abramowicz, Nilufer Broeders, Alain Lemoine, Patrick Peeters, Steven Van Laecke, Laurent E. Weekers, Jacques Sennesael, Karl M. Wissing, Caroline Geers, Jean-Louis Bosmans
Summary: Withdrawal of steroids or switching to everolimus instead of cyclosporine are two effective strategies to reduce treatment-related side effects and improve long-term outcomes of kidney transplantation. Both regimens provide similar 5-year patient survival and death-censored graft survival, but the everolimus group showed higher (51)CrEDTA clearance at 1 and 5 years post-transplantation.
TRANSPLANT INTERNATIONAL
(2021)
Review
Oncology
Qian Luo, Ruijuan Du, Wenting Liu, Guojing Huang, Zigang Dong, Xiang Li
Summary: Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer worldwide, mainly occurring in specific regions of Asia. The PI3K/Akt/mTOR signaling pathway plays a crucial role in regulating cell growth, differentiation, migration, metabolism, and proliferation, and is closely associated with survival and prognosis in ESCC patients. Many molecules can regulate this pathway and lead to its aberrant activation. Several effective inhibitors of the PI3K/Akt/mTOR pathway have been developed.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Katarzyna Bobeff, Karolina Krajewska, Dobromila Baranska, Katarzyna Kotulska, Sergiusz Jozwiak, Wojciech Mlynarski, Joanna Trelinska
Summary: The study indicates that maintenance therapy with everolimus may be an effective therapeutic option for patients with tuberous sclerosis and subependymal giant cell astrocytoma, providing a certain level of efficacy and safety, stabilizing the condition, and with a lower frequency of adverse events during maintenance therapy. It is recommended to carefully monitor for possible disease progression during maintenance therapy, especially in the first six months.
FRONTIERS IN NEUROLOGY
(2021)
Article
Urology & Nephrology
Elisabetta Bussalino, Luigina Marsano, Angelica Parodi, Rodolfo Russo, Fabio Massarino, Maura Ravera, Gabriele Gaggero, Iris Fontana, Giacomo Garibotto, Gianluigi Zaza, Giovanni Stallone, Ernesto Paoletti
Summary: Switching kidney transplant recipients with BKVN from standard treatment to Everolimus therapy effectively improved renal function, reduced virus replication, and enhanced transplant survival rate.
JOURNAL OF NEPHROLOGY
(2021)
Review
Immunology
Gabriel Orozco, Meera Gupta, Roberto Gedaly, Francesc Marti
Summary: This review discusses the major challenges that Treg cell transplant investigators currently face, including Treg cell diversity, manufacturing process, administration route, and lack of effective monitoring and biomarkers.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Masatsugu Miyashita, Teruki Shimizu, Eishi Ashihara, Osamu Ukimura
Summary: Human gamma delta T cells exhibit potent cytotoxicity against various types of cancer cells in an MHC-unrestricted manner. Activation of gamma delta T cells can be achieved via phosphoantigens and N-bis interacting with BTN3A1 on target cells. Co-immunotherapy with gamma delta T cells and immune checkpoint inhibitors may enhance cytotoxicity against cancer cells. Strategies such as the use of bispecific antibodies and chimeric antigen receptors should be further studied in a clinical research setting to overcome current therapeutic limitations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Lipei Shao, Avinash Iyer, Yingdong Zhao, Rob Somerville, Sandhya Panch, Alejandra Pelayo, David F. Stroncek, Ping Jin
Summary: The study identified genomic signatures associated with clinical remission in patients undergoing CD19 CAR T-cell therapy by analyzing the transcriptomic profile of bone marrow before lymphodepleting preconditioning. Patients achieving complete response showed increased activity in genes related to T cell activation, chemokine, and interleukin signaling pathways, while non-responding patients exhibited higher activity in cell cycle checkpoint pathways. Additionally, a 14-gene signature was identified as a remission-marker.
SCIENTIFIC REPORTS
(2022)
Article
Pharmacology & Pharmacy
Ying-hua He, Guo Tian
Summary: Autophagy plays a crucial role in renal cell carcinoma, with many autophagy-related proteins serving as prognostic markers. Researchers are exploring synthetic and phytochemical drugs targeting autophagy for RCC therapy.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru P. Sonpavde
Summary: The study investigated the relationship between gene expression and treatment benefit of Everolimus in metastatic renal cell carcinoma patients. Specific gene signatures were identified that could potentially predict the response to Everolimus monotherapy or combination therapy with a vascular disrupting agent. Further validation of these gene signatures is needed to determine their clinical utility in patient selection.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Mihail I. Mitov, Jennifer W. Harris, Michael C. Alstott, Yekaterina Y. Zaytseva, B. Mark Evers, D. Allan Butterfield
EXPERIMENTAL CELL RESEARCH
(2017)
Article
Toxicology
James T. F. Wise, Lei Wang, Michael C. Alstott, Ntube N. O. Ngalame, Yuting Wang, Zhuo Zhang, Xianglin Shi
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Chang Li, Yuning Zhou, Ji Tae Kim, Tomoko Sengoku, Michael C. Alstott, Heidi L. Weiss, Qingding Wang, B. Mark Evers
Summary: SIRT2 is a direct target gene of the Wnt/beta-catenin pathway and plays a crucial role in the differentiation of CRC cells. Inhibition or knockdown of SIRT2 can reduce the OXPHOS activity and differentiation of CRC cells.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2021)
Article
Oncology
Chontida Yarana, Dustin Carroll, Jing Chen, Luksana Chaiswing, Yanming Zhao, Teresa Noel, Michael Alstott, Younsoo Bae, Emily V. Dressler, Jeffrey A. Moscow, D. Allan Butterfield, Haining Zhu, Daret K. St Clair
CLINICAL CANCER RESEARCH
(2018)